• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

    0.2309 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gossamer Bio, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    These stocks are the most active in today's session ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
    Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 
    Via Stocktwits
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio to Participate in Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio to Participate in Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
     
    Via Benzinga
    News headline image
    Gossamer Bio to Present at Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.